Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Xtant Medical Holdings, Inc. (XTNT)

Xtant Medical gains exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows

Neutral Impact 3 of 5 product/contract Written later

Xtant Medical entered a distribution agreement dated April 10, 2026 with Dilon Technologies, giving Xtant exclusive U.S. rights to import, market, distribute and sell the FDA-approved HEMOBLAST Bellows hemostatic powder. Xtant also hired about 20 Dilon sales personnel and plans to update its full-year 2026 guidance with its first quarter 2026 results, so shareholders will see the financial effect when that guidance is released.

Key points

  • Xtant paid Dilon a $5.0 million exclusivity fee, which Dilon may have to repay in certain circumstances, including termination of the agreement.
  • Xtant hired approximately 20 Dilon sales personnel to sell the product in the United States.
  • Dilon will continue to manufacture HEMOBLAST Bellows in France and sell it to Xtant at a transfer price that can change under the agreement.
  • The agreement has no minimum purchase requirements for Xtant; Xtant plans to update 2026 guidance with its Q1 2026 results.

The filing

CompanyXtant Medical Holdings, Inc. (XTNT)
Form8-K, current report
Filed with the SECApr 13, 2026, 9:20 AM ET
Accession number0001493152-26-016308

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.